Scarica l'app Stockscreener
25.36
1.17%
-0.30
Precedente Chiudi:
$25.66
Aprire:
$25.5
Volume 24 ore:
226.89K
Relative Volume:
1.51
Capitalizzazione di mercato:
$1.53B
Reddito:
-
Utile/perdita netta:
$-209.84M
Rapporto P/E:
-5.5492
EPS:
-4.57
Flusso di cassa netto:
$-6.73M
1 W Prestazione:
+2.46%
1M Prestazione:
+1.12%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$25.26
$26.29
Intervallo di 1 settimana:
$22.90
$26.29
Portata 52W:
$16.50
$28.76
Damora Therapeutics Inc Stock (DMRA) Company Profile
Nome
Damora Therapeutics Inc
Settore
Industria
Telefono
(781) 281-9020
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
25.36 | 1.53B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-03-25 | Iniziato | Evercore ISI | Outperform |
| 2026-02-17 | Iniziato | UBS | Buy |
| 2026-01-07 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Iniziato | Guggenheim | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-23 | Iniziato | BofA Securities | Buy |
| 2020-11-23 | Iniziato | Credit Suisse | Outperform |
| 2020-11-23 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Damora Therapeutics Inc Borsa (DMRA) Ultime notizie
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Two new Damora hires get stock options for 57,500 shares - Stock Titan
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Damora Therapeutics (NASDAQ: DMRA) sets 2026 virtual meeting, director votes and say-on-pay - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Upgraded at Royal Bank Of Canada - MarketBeat
DMRA Initiated Coverage by RBC Capital -- Price Target Set at $4 - GuruFocus
Royal Bank Of Canada Begins Coverage on Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) - MarketBeat
RBC Initiates Damora Therapeutics at Outperform, Speculative Risk With $40 Price Target - marketscreener.com
Paramora Holding LLC owns 2,045,473 shares — Damora (NASDAQ: DMRA) - Stock Titan
RBC initiates Damora Therapeutics stock at Outperform, $40 target By Investing.com - Investing.com South Africa
RBC initiates Damora Therapeutics stock at Outperform, $40 target - Investing.com UK
Damora Therapeutics Inc (DMRA) Stock Price & 30 Year Financial Data - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) 10K Form and Latest SEC Filings 2026 - MarketBeat
DMRA Price History for Damora Therapeutics Stock - Barchart.com
Damora Therapeutics (NASDAQ: DMRA) replaces EY Denmark with EY US - Stock Titan
Klein Hersh Places President and CEO for Damora Therapeutics - Hunt Scanlon Media
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Forecast and Price Target 2026 - MarketBeat
Damora (DMRA) Stock: Hold Signals (Trend Weakens) 2026-04-15Volume Leaders - Newser
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Short Interest Update - MarketBeat
Certain Warrants of Galecto, Inc. are subject to a Lock-Up Agreement Ending on 12-APR-2026. - marketscreener.com
Certain Stock Options of Galecto, Inc. are subject to a Lock-Up Agreement Ending on 12-APR-2026. - marketscreener.com
Certain Common Stock of Galecto, Inc. are subject to a Lock-Up Agreement Ending on 12-APR-2026. - marketscreener.com
Is Damora Therapeutics’ (DMRA) New CEO and Fast Track Status Reframing Its Pipeline Execution Story? - Sahm
Damora Therapeutics Inc (DMRA) Stock Earnings Transcripts - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) Financials 2026Income Statement and Balance Sheet - MarketBeat
Will Damora (DMRA) Stock Go Higher | Price at $25.70, Up 0.39%Strong Buy Rating - Newser
Is Damora (DMRA) Stock Consolidating | Price at $24.57, Down 2.07%Risk Analysis - Newser
Spyre Therapeutics Announces Grants of Inducement Awards - marketscreener.com
Damora Therapeutics Inc Azioni (DMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Damora Therapeutics Inc Azioni (DMRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
8,713,000 |
0 |
5,809,000 |
| Schambye Hans T. | Chief Executive Officer |
Jan 02 '26 |
Sale |
21.38 |
700 |
14,966 |
4,682 |
| Winslow Garrett | General Counsel |
Jan 02 '26 |
Sale |
21.38 |
255 |
5,452 |
1,854 |
| Firmani Lori | Chief Financial Officer |
Jan 02 '26 |
Sale |
21.41 |
135 |
2,890 |
931 |
| Schambye Hans T. | Chief Executive Officer |
Jul 03 '25 |
Sale |
3.38 |
735 |
2,484 |
4,022 |
| Winslow Garrett | General Counsel |
Jul 03 '25 |
Sale |
3.39 |
260 |
881 |
1,429 |
| Firmani Lori | Interim CFO |
Jul 03 '25 |
Sale |
3.39 |
147 |
498 |
692 |
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):